...
首页> 外文期刊>British Journal of Pharmaceutical Research >Herbal Drug Development from Traditional Formulations: Refocusing Pharmaceutics and Posology for Accelerated Validation
【24h】

Herbal Drug Development from Traditional Formulations: Refocusing Pharmaceutics and Posology for Accelerated Validation

机译:从传统配方中开发草药:重新聚焦药物和药理学以加速验证

获取原文
           

摘要

Background: The World Health Organization (WHO) recommended that the toxicity data of a traditional medicine (TM) product that has been in use for 20 years or more without untoward effects should be determined, as the first step in its research and development (R&D). Such data in conjunction with efficacy data would be used to develop an appropriate dosage form of the product. A key objective in researching such a product is to validate the basis of the therapy, including the formula. Such validation, and any attempt to modernize the product, should be guided by an understanding of the traditional know-how. The Nigerian National Institute for Pharmaceutical Research and Development (NIPRD) utilized this approach in developing Niprisan, an antisickling drug, based on a TM product used since antiquity in Yoruba Medicine. Aim: This article aimed to advocate the continuance and improvement of the WHO model of herbal drug research and regulation (HDRR) as the most logical approach for adoption by researchers and regulators. Methodology: NIPRD’s adoption of the WHO model since 1989 was reviewed in parallel with trends in herbal drug research worldwide; and within the contexts of regulatory practices by Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) and the European Medicines Evaluation Agency (EMEA), with a view to identifying more effective strategies within the WHO paradigm for HDRR. Conclusion: Drug regulatory agencies (DRAs) like NAFDAC require effective laws, policies and quality management systems (QMS) to execute their mandates effectively. On the other hand, NIPRD’s output depends upon proper actions by a seasoned and responsive DRA. Therefore, noting that NIPRD and NAFDAC were both created by military decrees in 1989 and 1992 respectively, rather than by parliament acts, it is recommended that in addition to instituting more effective laws and policies to regulate NAFDAC, both NIPRD and NAFDAC need to adopt and implement suitable QMS for self-regulation, eg: ISO 9001 for whole organizations; and ISO/IEC 17250 for the laboratories.
机译:背景:世界卫生组织(WHO)建议,应确定已使用20年或更长时间且无不良影响的传统药物(TM)产品的毒性数据,作为其研发(研发)的第一步。 )。此类数据与功效数据一起将用于开发产品的合适剂型。研究此类产品的关键目标是验证疗法的基础,包括配方。此类验证以及对产品进行现代化改造的任何尝试都应以对传统知识的理解为指导。尼日利亚国家药品研究与开发研究所(NIPRD)利用这种方法开发了抗腐药物Niprisan,它基于自约鲁巴医学以来就一直使用的TM产品。目的:本文旨在倡导继续和改进WHO草药研究与监管(HDRR)模式,这是研究人员和监管机构采用的最合乎逻辑的方法。方法:NIPRD自1989年以来采用的WHO模式与世界范围内草药研究的趋势同时进行了回顾;并在尼日利亚国家食品药品监督管理局(NAFDAC)和欧洲药品评估局(EMEA)的监管措施范围内,以期在WHO的HDRR范式中确定更有效的策略。结论:像NAFDAC这样的药物监管机构(DRA)需要有效的法律,政策和质量管理体系(QMS)来有效地执行其任务。另一方面,NIPRD的输出取决于经验丰富且反应迅速的DRA采取的适当行动。因此,注意到NIPRD和NAFDAC都是分别由1989年和1992年的军事法令而非议会法案创建的,因此建议除了制定更有效的法律和政策来规范NAFDAC之外,NIPRD和NAFDAC都需要采用和实施适当的质量管理体系以进行自我监管,例如:整个组织均通过ISO 9001;实验室的ISO / IEC 17250标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号